Zobrazeno 1 - 10 of 49 pro vyhledávání: '"Javier Hornedo"'
1
Akademický článek
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgementResearch in context
Autor: Ramon Colomer, Jesús Miranda, Nuria Romero-Laorden, Javier Hornedo, Lucía González-Cortijo, Silvana Mouron, Maria J. Bueno, Rebeca Mondéjar, Miguel Quintela-Fandino
Publikováno v: EClinicalMedicine, Vol 60, Iss , Pp 102029- (2023)
Summary: Background: Next Generation Sequencing (NGS) panels are increasingly used in advanced patients with cancer to guide therapy. There is, however, controversy about when should these panels be used, and about their impact on the clinical course
Externí odkaz: https://doaj.org/article/a6a92d1fa21047f4a65d551afa0d3bed
Zobrazit plný text záznamu
2
Akademický článek
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Autor: Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes
Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)
Abstract Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and b
Externí odkaz: https://doaj.org/article/3f6add655fbe4b0d92de37dd9a97fca3
Zobrazit plný text záznamu
3
Akademický článek
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
Autor: Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer, Juan Guerra
Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Abstract Background The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulat
Externí odkaz: https://doaj.org/article/1917c626fbb948caba36756bcb86cc27
Zobrazit plný text záznamu
4
Akademický článek
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
Autor: H. Jan Keizer, Derek Crowther, Ole Steen Nielsen, Allan T. Van Oosterom, Javier Hornedo Muguiro, Christine Van Pottelberghe, Renier Somers, Thomas Tursz
Publikováno v: Sarcoma, Vol 1, Iss 2, Pp 99-101 (1997)
Purpose. This study investigates the efficacy and toxicity of daily oral etoposide in chemotherapy for non-heavily pretreated advanced and metastatic soft tissue sarcoma (STS).
Externí odkaz: https://doaj.org/article/0e73ffa9b99246b68b4408694ee6a1e8
Zobrazit plný text záznamu
6
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Autor: Esther Holgado, Orlando Dominguez, Juan V. Apala, Javier Cortes, Diego Malón, Santos Mañes, Luis Manso, Serafin Morales, Silvana Mouron, Antonio Lopez-Alonso, M. I. Martínez, Ramon Colomer, Javier Hornedo, Raquel Blanco, Ariadna Gasol Cudós, Begoña Bermejo, Lucía González-Cortijo, Vega Iranzo, Manuel Muñoz, María del Carmen Moreno-Ortiz, Eduardo Caleiras, Miguel Quintela-Fandino
Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repisalud
Instituto de Salud Carlos III (ISCIII)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
BREAST CANCER RESEARCH
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Breast Cancer Research : BCR
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)
Scientia
© The Author(s).
[Background]: Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842a246ba615e772839387f7783c0eec
https://hdl.handle.net/20.500.12530/54354
Zobrazit plný text záznamu
7
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Autor: Stefano Iacobelli, Malgorzata Foszczynska-Kloda, Soo-Chin Lee, Richard A. Michaelson, Juan Lacava, Raymond Smith, Vichien Srimuninnimit, Mauricio Kotliar, William Audeh, Damir Vrbanec, Young-Hyuck Im, Paola Edith Price, Maria Del Pilar, Barbara Bower, Tadeusz Pienkowski, Jedzada Maneecahvakajorn, Seppo Pyrhoenen, Alexander Marmé, Saverio Cinieri, Vladimir Semiglazov, Luciano Latini, Luis Miguel, Thitiya Sirisinha, Mario Matwiejuk, Jose Luiz Pedrini, John Allan Ellerton, Maik Hauschild, Xiaojia Wang, Christoph Maintz, Joohyuk Sohn, Estefania Monturus, Kenjiro Aogi, Eugeny Gotovkin, Ron Blachy, Douglas Otero Reye, Rita Blanchard, Bahriye Aktas, Adam Knott, Norberto Batista Lopez, L Roman, Reiki Nishimura, Piotr Tomczak, Duncan Wheatley, Emilio Alba Conejo, Yoshinori Itoh, Giraldo Kato, Petar Stefanovski, Rosa Jochim, Christoph Thomssen, Brigitte Van Eyll, Yutaka Tokuda, S O'Reilly, Paulette Blanchet, Ion Boiangiu, Nikola Vasev, Sherko Kümmel, Julie Taguchi, Do Youn Oh, David Miles, Jurandyr Andrade, Nora Giacomi, Volkmar Mueller, Eduardo Côrtes, Paula Klein, Eleonora Restuccia, Xuenong Ouyang, Leanne Budde, Andre Kallab, Elżbieta Starosławska, Takayuki Ueno, Taral Patel, Jun Horiguchi, Gilson Delgado, Sue Prill, Carol Peterson, Lourdes Calvo, Andreas Kirsch, Gustavo Ismael, Liwei Wang, Veena Charu, Dino Amadori, Pirkko Kellokumpu-Lehtinen, Brooke R. Daniel, Frank Senecal, Sanjay Yadav, Vera Gorbunova, Mikhail Kopp, Patrapim Sunpaweravong, Hiroji Iwata, Frank Priou, Kazuhiko Nakagami, Alejandra Perez, Michael R. Clemens, Marcus Schmidt, Denise A. Yardley, Birgitta Wesenberg, Priscilla Caguioa, Haruki Ogata, An Nguyen, Sung Bae Kim, Tsz-Kok Yau, Vladimir Merculov, Mikhail Lichinitser, Valorie Chan, Yoshiaki Rai, Neville Davidson, Walter E. Aulitzky, Gloria Martinez, Koji Takeda, Sherene Loi, Junichiro Watanabe, Louis Fehrenbacher, Gunta Purkalne, Shaker R. Dakhil, Claudia Schumacher, Rizvana Ahmad, Winnie Yeo, Christine Brezden-Masley, Alison Jones, Seock-Ah Im, Zetina Toache, Jeffrey Hargis, Celia Tosello, Tania Soria, Catia Angiolini, Maria De Fatima Gaui, Ravi Patel, Christopher Lobo, Andreas Schneeweiss, Priyanka Sharma, Cesar Estuardo, Randall Thomas, Adam Brufsky, Virote Sriuranpong, Zhenzhou Shen, Sandra Franco, Clive Mulatero, Wojciech Polkowski, Maria Alejandra Bartoli, Shigehira Saji, Patrick J. Flynn, Kimberly L. Blackwell, Gladys Rodriguez, Robert Robles, Timothy J. O'Rourke, Fabio Franke, Gabriel Tellez-Trevilla, Robert R. Carroll, Laura Biganzoli, Cheng Ying, Peter A. Kaufman, Mark Karwal, Mirta Varela, Darcy Spicer, Jonathan Polikoff, Roberto Hegg, Jungsil Ro, Pedro Sánchez-Rovira, Takahiro Nakayama, Edda Simoncini, María Bianconi, Liljana Kostovska-Maneva, Hugo Castro, Elza Grincuka, Jeff Neidhart, Anne Robinson, Nathan B. Green, Robert Hermann, Laura Assersohn, Teresa Gamucci, Dennis Tudtud, Nobuaki Sato, Antonio Gonzalez Martin, Victor Hugo Alencar, Jess Armor, Bruno Coudert, Nuria Ribelles, Eva Ciruelos, Daniel Cubero, Iveta Kudaba, Eduardo Cronemberger, Norikazu Masuda, Norio Kohno, Sergio J Azevedo, Vadim Shirinkin, Miguel Gil I Gil, Serafin Morales, Hirofumi Fujii, Chris Gallagher, Hernandez Monroy, Katsumasa Kuroi, Rodrigo Moura, Richy Agajanian, Zeljko Soldic, Jean-Marc Ferrero, Kenichi Inoue, Mark C. Benyunes, Davi Jendiroba, Filippo Montemurro, Masahiro Kashiwaba, Robert Quackenbush, Koichiro Tsugawa, Paulo M. Hoff, Eva-Maria Grischke, Susana De La Cruz, Vincent Hansen, Marianna Bitina, Carolyn B. Hendricks, Javier Cortes, Zee Wan Wong, Igor Kiselev, David Waterhouse, Javier Hornedo Muguiro, Mario Campone, Marianne Just, Emma Clark, Rodrigo Pereira, Sandra M Swain, Ruemu E. Birhiray, Helio Pinczowski, Wichit Arpornwirat
Publikováno v: The Lancet. Oncology. 21(4)
Summary Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. In the primary analysis and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e284b6f4b09c71b9922a7f657773bd0
https://pubmed.ncbi.nlm.nih.gov/32171427
Zobrazit plný text záznamu
8
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
Autor: Ramon Colomer, Juan V. Apala, Diego Malón, Juan Antonio Guerra, Miguel Quintela-Fandino, Javier Hornedo, Silvana Mouron, Lucía González-Cortijo
Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)
Breast Cancer Research : BCR
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0f93139d823603dba7e38d119714d5
http://hdl.handle.net/20.500.12105/7806
Zobrazit plný text záznamu
9
Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Autor: Ricardo Sainz de la Cuesta, Gines Hernandez-Cortes, R. Murillo, Lucía González-Cortijo, Javier Hornedo
Publikováno v: Journal of Gynecology and Obstetrics. 9:139
Introduction: Triple negative breast cancer (TNBC) has been classically considered a high-risk subtype. Early TNBC is usually managed with neoadjuvant chemotherapy (NAC). Residual disease after NAC is generally considered a surrogate marker for event
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78365bae145fc3eeb57a2b79ae8a5203
https://doi.org/10.11648/j.jgo.20210905.11
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje